View ValuationCytoDyn 将来の成長Future 基準チェック /06現在、 CytoDynの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesCytoDyn Inc Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast CancerApr 29CytoDyn Inc. Completes Enrollment in Phase 2 Metastatic Colorectal Cancer StudyApr 24CytoDyn Inc Presents New Leronlimab Data in Metastatic Colorectal CancerApr 22CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026Apr 21CytoDyn Inc. Presents Preclinical Data On Leronlimab-Mediated Ccr5 Inhibition In GlioblastomaMar 25Cytodyn Inc. Presents Novel Ccr5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer At Aacr Immuno-Oncology ConferenceFeb 21CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer SymposiumDec 09CytoDyn Announces Resolution of Class Action LawsuitDec 02Cytodyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer At the San Antonio Breast Cancer SymposiumNov 25CytoDyn Inc. announced that it expects to receive $30 million in funding from Yorkville Advisors Global LPNov 04CytoDyn Inc. to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special ConferenceSep 26CytoDyn Inc., Annual General Meeting, Nov 21, 2025Sep 22CytoDyn Inc. to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related AutoimmunitySep 16Cytodyn Inc. Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with LeronlimabJul 02CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal CancerJun 25CytoDyn Inc. Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid TumorsMay 14CytoDyn Inc. Announces Chief Financial Officer ChangesMay 06CytoDyn Inc. Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFeb 24Cytodyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with Smc LaboratoriesFeb 06CytoDyn Inc. Announces FDA Clearance of its Phase II Oncology TrialNov 05CytoDyn Inc., Annual General Meeting, Nov 22, 2024Oct 14CytoDyn Appoints Max Lataillade as Senior Vice President and Head of Clinical DevelopmentOct 08CytoDyn Inc. Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal CancerAug 13CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH StudyJun 27CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaFeb 02CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEOJan 30+ 1 more updateCytoDyn Inc. Announces Lawsuit UpdateDec 23CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEONov 22CytoDyn Inc. announced delayed 10-Q filingOct 17CytoDyn Inc., Annual General Meeting, Nov 09, 2023Sep 26CytoDyn Inc. announced delayed annual 10-K filingSep 01CytoDyn Inc. Announces CEO ChangesJul 12+ 1 more updateCytoDyn Inc. Announces Executive ChangesMay 25CytoDyn Inc. Announces Resignation of Scott A. Kelly, Chief Medical OfficerDec 21Nitya G. Ray Resigns as Chief Technology Officer of CytoDyn IncNov 26CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management IssuesOct 29CytoDyn Inc., Annual General Meeting, Dec 09, 2022Oct 27CytoDyn Inc. Announces Board ChangesOct 20CytoDyn Inc. Approves the Appointment of Ryan Dunlap as DirectorAug 31CytoDyn Inc. announced delayed annual 10-K filingAug 02CytoDyn Inc. Appoints Cyrus Arman as PresidentJul 14CytoDyn Inc. Announces Preclinical Study in Nonhuman Primates That Will Evaluate the Potential Use in HIV of a Gene Therapy Based on the Experimental Monoclonal Antibody LeronlimabJul 12CytoDyn Inc. Announces Resignation of Jordan G. Naydenov as Board memberMay 24CytoDyn Inc. announced that it expects to receive $4.785 million in fundingMay 06CytoDyn Inc. Announces Executive ChangesApr 26CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 ProgramMar 31CytoDyn Inc. Announces Research Paper Published Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 from Heavily Treatment Experienced SubjectsJan 12CytoDyn Inc. Announces Positive Results from the 350 Mg Weekly Dose of Its Phase 2 NASH Clinical TrialJan 06CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill PopulationDec 22ytoDyn Inc. Announces Additional Preliminary Results to Date from 20 Patients Who Have Completed Open-Label Portion of Phase 2 Trial for NASHDec 14CytoDyn Inc. Submits Protocol with FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 PopulationDec 10+ 1 more updateCytodyn’S Cro in Brazil Met with Anvisa to Modify Cd16 Trial for Critically Ill Covid-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022Dec 09CytoDyn Inc. Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA SubmissionDec 02CytoDyn Inc. Reports Data from Its Trial Treating NASH Open Label with LeronlimabNov 25CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint BlockadeOct 08CytoDyn Inc. Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with Iv Administration of Four Doses (700Mg/Week)Sep 24Group of CytoDyn Inc. Stockholders Announces Federal Court Dismisses Litigation Brought by CompanySep 23+ 1 more updatePaul A. Rosenbaum Provides Information to Shareholders of CytoDynSep 20CytoDyn Inc. Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe SymptomsSep 11CytoDyn Inc. announced that it has received $3.872 million in fundingSep 08+ 1 more updateGroup of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director NomineesAug 27CytoDyn Inc. Updates Preliminary Results from Phase 1B/2 TrialsAug 26CytoDyn Provides Update on Rosenbaum and Patterson Group LitigationAug 20Paul A. Rosenbaum Provides Information to the ShareholdersAug 18Paul A. Rosenbaum Provides Information to the ShareholdersAug 14+ 1 more updateCytoDyn Inc. Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 PatientsAug 05Paul Rosenbaum Issues a Statement to Press OutletsAug 04CytoDyn Inc. Announces Preliminary Results from 30 Mtnbc Patients Treated with LeronlimabJul 20CytoDyn Inc. Announces Advance from Phase 1B to Phase 2 Trial of Its Clinical Trial with Leronlimab in Combination with Carboplatin for the Treatment of Metastatic Triple-Negative Breast CancerJul 14CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIVJul 03CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 SymptomsJun 22CytoDyn Inc. Announces Publication in Nature Communications of A Study Showing leronlimab Preventing HIV Infection in PrimateJun 08CytoDyn Inc. Conducting a Phase 2 Clinical Trial for nonalcoholic steatohepatitis to Evaluate the Effect of Leronlimab on Liver Steatosis and FibrosisJun 02CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and PhilippinesMay 19Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against CytoDyn, IncMay 17CytoDyn Inc. announces HIV Indication UpdateMay 04+ 1 more updateThe Portnoy Law Firm Announces Last Days to Participate Actively in the Class Action Lawsuit Against CytoDyn, IncApr 09CytoDyn Inc. announced that it has received $25 million in fundingApr 07Scott+Scott Attorneys at Law LLP Files Securities Class Action Against CytoDyn, IncMar 19CytoDyn Inc. Appoints Christopher P. Recknor as Chief Operating OfficerMar 17CytoDyn Inc.’s Long-Haulers COVID-19 Trial Enrolled 20 Patients Within 10 DaysMar 12CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, March 8Mar 09+ 1 more updateCytoDyn Inc.'s Phase 3 Trial Demonstrates Safety, A 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill Covid-19 Patients Treated with LeronlimabMar 07CytoDyn Inc. in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 PatientsFeb 23Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit to Access Cytodyn’s Leronlimab for Covid-19 PatientsJan 31FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 PatientsJan 01FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 TrialDec 23CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19Dec 17CytoDyn Inc. Announces First Patient Enrolled in Phase 2 Trial for NashDec 03CytoDyn Inc. Announces Partnership with amFAR to Accelerate HIV Cure ResearchNov 25CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This YearNov 24CytoDyn Inc. Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler SymptomsNov 18 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、CytoDyn は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:CYDY - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数2/28/2026N/A-40-18-18N/A11/30/2025N/A-40-17-17N/A8/31/2025N/A-23-17-17N/A5/31/2025N/A2-9-9N/A2/28/2025N/A-9-5-5N/A11/30/2024N/A-16-2-2N/A8/31/2024N/A-21-1-1N/A5/31/2024N/A-51-11-11N/A2/29/2024N/A-53-13-13N/A11/30/2023N/A-55-17-17N/A8/31/2023N/A-73-19-19N/A5/31/2023N/A-87-25-25N/A2/28/2023N/A-152-28-28N/A11/30/2022N/A-180-33-33N/A8/31/20220-192-57-57N/A5/31/20220-212-78-78N/A2/28/20220-195-105-104N/A11/30/20210-198-117-117N/A8/31/20210-193-108-108N/A5/31/2021N/A-178-118-118N/A2/28/2021N/A-169-114-114N/A11/30/2020N/A-160-108-108N/A8/31/2020N/A-139-95-95N/A5/31/2020N/A-141-69-69N/A2/29/2020N/A-82-49-49N/A11/30/2019N/A-58N/A-46N/A8/31/2019N/A-58N/A-57N/A5/31/2019N/A-56N/A-50N/A2/28/2019N/A-51N/A-48N/A11/30/2018N/A-56N/A-43N/A8/31/2018N/A-53N/A-32N/A5/31/2018N/A-50N/A-30N/A2/28/2018N/A-47N/A-30N/A11/30/2017N/A-38N/A-29N/A8/31/2017N/A-32N/A-27N/A5/31/2017N/A-26N/A-27N/A2/28/2017N/A-25N/A-25N/A11/30/2016N/A-22N/A-27N/A8/31/2016N/A-22N/A-26N/A5/31/2016N/A-26N/A-25N/A2/29/2016N/A-33N/A-24N/A11/30/2015N/A-31N/A-15N/A8/31/2015N/A-31N/A-15N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CYDYの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CYDYの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CYDYの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CYDYの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CYDYの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CYDYの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 12:20終値2026/05/01 00:00収益2026/02/28年間収益2025/05/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CytoDyn Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
CytoDyn Inc Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast CancerApr 29
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026Apr 21
Cytodyn Inc. Presents Novel Ccr5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer At Aacr Immuno-Oncology ConferenceFeb 21
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer SymposiumDec 09
Cytodyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer At the San Antonio Breast Cancer SymposiumNov 25
CytoDyn Inc. announced that it expects to receive $30 million in funding from Yorkville Advisors Global LPNov 04
CytoDyn Inc. to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special ConferenceSep 26
CytoDyn Inc. to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related AutoimmunitySep 16
Cytodyn Inc. Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with LeronlimabJul 02
CytoDyn Inc. Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid TumorsMay 14
CytoDyn Inc. Announces Promising Survival Observations in mTNBC Patients Treated with LeronlimabFeb 24
Cytodyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with Smc LaboratoriesFeb 06
CytoDyn Inc. Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal CancerAug 13
CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in GlioblastomaFeb 02
CytoDyn Inc. Announces Preclinical Study in Nonhuman Primates That Will Evaluate the Potential Use in HIV of a Gene Therapy Based on the Experimental Monoclonal Antibody LeronlimabJul 12
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 ProgramMar 31
CytoDyn Inc. Announces Research Paper Published Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 from Heavily Treatment Experienced SubjectsJan 12
CytoDyn Inc. Announces Positive Results from the 350 Mg Weekly Dose of Its Phase 2 NASH Clinical TrialJan 06
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill PopulationDec 22
ytoDyn Inc. Announces Additional Preliminary Results to Date from 20 Patients Who Have Completed Open-Label Portion of Phase 2 Trial for NASHDec 14
CytoDyn Inc. Submits Protocol with FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 PopulationDec 10+ 1 more update
Cytodyn’S Cro in Brazil Met with Anvisa to Modify Cd16 Trial for Critically Ill Covid-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022Dec 09
CytoDyn Inc. Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA SubmissionDec 02
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint BlockadeOct 08
CytoDyn Inc. Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with Iv Administration of Four Doses (700Mg/Week)Sep 24
Group of CytoDyn Inc. Stockholders Announces Federal Court Dismisses Litigation Brought by CompanySep 23+ 1 more update
CytoDyn Inc. Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe SymptomsSep 11
Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director NomineesAug 27
CytoDyn Inc. Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 PatientsAug 05
CytoDyn Inc. Announces Advance from Phase 1B to Phase 2 Trial of Its Clinical Trial with Leronlimab in Combination with Carboplatin for the Treatment of Metastatic Triple-Negative Breast CancerJul 14
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIVJul 03
CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 SymptomsJun 22
CytoDyn Inc. Announces Publication in Nature Communications of A Study Showing leronlimab Preventing HIV Infection in PrimateJun 08
CytoDyn Inc. Conducting a Phase 2 Clinical Trial for nonalcoholic steatohepatitis to Evaluate the Effect of Leronlimab on Liver Steatosis and FibrosisJun 02
CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and PhilippinesMay 19
Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against CytoDyn, IncMay 17
The Portnoy Law Firm Announces Last Days to Participate Actively in the Class Action Lawsuit Against CytoDyn, IncApr 09
CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, March 8Mar 09+ 1 more update
CytoDyn Inc.'s Phase 3 Trial Demonstrates Safety, A 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill Covid-19 Patients Treated with LeronlimabMar 07
CytoDyn Inc. in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 PatientsFeb 23
Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit to Access Cytodyn’s Leronlimab for Covid-19 PatientsJan 31
FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 PatientsJan 01
FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 TrialDec 23
CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19Dec 17
CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This YearNov 24
CytoDyn Inc. Files Protocol with U.S. FDA for Phase 2 Clinical Trial for COVID-19 Patients with Long-Hauler SymptomsNov 18